2013 Annual Cancer Report
“Sometimes, reaching out and taking someone’s hand is the beginning of a journey. At other times, it is allowing another to take yours.”
- Vera Nazarian
Letter to Stakeholders At the Cone Health Cancer Center, our goal is to provide you with holistic cancer care that meets the highest quality standards, and the American College of Surgeons Commission on Cancer (CoC) says that we are succeeding. In 2012, this organization awarded us a threeyear accreditation with commendation and subsequently gave us its Outstanding Achievement Award, an honor that goes to only 14 percent of the 1,500 cancer centers in the United States and Puerto Rico accredited by the CoC. In addition, our breast cancer program earned accreditation for the first time from the National Accreditation Program for Breast Centers. These two accreditations show our continued emphasis on providing exceptional cancer care. They are a great way for you to know that the high-quality cancer care in our community meets and exceeds the accreditation standards for top-tier cancer centers. We constantly challenge ourselves to improve the care we provide our patients. The treatment results we achieve are real signs that we are dedicated to you and your care. When it comes to cancer, quality is defined in part by how well you treat the whole person, not just the disease. Toward that end, we are continuously adding programs and services that patients and their families often need to support their mental and emotional well-being. The GYN Care Group is among our newest programs. The GYN Care Group is a support group for women who are currently or have been in treatment for gynecological cancer. This group meets in a welcoming environment to exchange thoughts, give and receive support, and reach out to others who share this life challenge. We also offer on-site cancer risk assessments and genetic counseling for those who believe they may be at risk for cancer. Many forms of cancer are caused by hereditary traits, and some are the result of an altered gene passed from parent to child, either from the father’s or mother’s side of the family. Our specially trained counselor assesses your risk through a variety of tests and offers guidance based on the test results. This service provides you with peace of mind or an early warning for screening and detection.
Never forget where you’ve been. Never lose sight of where you’re going. And never take for granted the people who travel the journey with you. - Ritu Ghatourey 2
Of course, the medical services we offer are a significant part of our cancer care.
Medical/Hematology Oncology Our medical and hematology oncology care providers work in teams, with each team specializing in only one or two types of cancers of the blood and related disorders. In addition, we have a dedicated on-site laboratory that oversees blood product transfusions and procedures.
Chemotherapy We provide a specialized area for chemotherapy treatments adjacent to our in-house laboratory where the chemotherapy medications are compounded. Each of our private and spacious patient treatment pods has a flat screen television and work area.
Gynecologic Oncology
Shadad
Hislop
Byerly
Three board-certified gynecologic oncologists provide subspecialty consultative and surgical services. These medical experts are supported by a clinical nurse specialist and nurse practitioner. This dedicated team provides patient and family education, problem intervention, home planning and care, and telephone triage during treatment or post-surgery.
Radiation Oncology Cone Health offers the latest in radiation therapy technologies, including several firsts for the state of North Carolina. While other cancer programs in our area may offer one or two specialized technologies, we offer the full array of the most state-of-the-art technology available today, such as TomoTherapy and TrueBeam STx. In the following pages, you’ll see why we are proud of the work we do. As you journey through this book, we also hope that you will draw inspiration, strength and courage from the quotations that are scattered throughout, because our holistic approach to cancer care not only heals the body, but also provides inspiration, strength and courage to the soul. If you or a loved one has cancer, we’d like to help. Please go to conehealth.com/cancer to learn more about our program.
Skip Hislop Firas Shadad, MD Vice President Chairman, Cancer Committee for Oncology Services Medical Oncologist Cone Health
Faera Byerly, MD Cancer Liaison Physician Surgical Oncologist
Cone Health is accredited by the American College of Surgeons Commission on Cancer and the National Accreditation Program for Breast Centers. The information published in the 2013 Annual Cancer Report is based on 2012 data.
3
Cone Health Cancer Center Tops in Quality Patient Care
Each year, we submit specific data to the National Cancer Data Base, which allows us to compare the effectiveness of our quality improvement measures against those of other cancer centers across the nation. The measures against which we benchmark ourselves are endorsed by the National Quality Forum. These measures not only emphasize the quality of patient care, but also the importance of accurate and complete documentation. The following charts demonstrate how Cone Health Cancer Center compares to similar programs and to all programs that have been approved by the American College of Surgeons Commission on Cancer. The charts also show what percentages of patients were affected.
Chemotherapy Administered Within 4 Months % Diagnosed Breast Cancer Patients 100% 95% 90% 85%
0% Cone Health Cancer Center
Similar Programs
All Commission on Cancer Approved Programs
Radiation Therapy Administered Within 1 Year
Hormone Therapy Administered Within 1 Year
% Diagnosed Breast Cancer Patients
% Diagnosed Breast Cancer Patients
100%
100%
95%
95%
90%
90%
85%
85%
0% Cone Health Cancer Center
Similar Programs
All Commission on Cancer Approved Programs
0% Cone Health Cancer Center
Similar Programs
All Commission on Cancer Approved Programs
“We should not judge people by their peak of excellence; but by the distance they have traveled from the point where they started.� - Henry Ward Beecher 4
Radiation Therapy Administered Within 6 Months % Diagnosed Rectal Cancer Patients 100% 95% 90% 85%
0% Cone Health Cancer Center
Similar Programs
All Commission on Cancer Approved Programs
Chemotherapy Administered Within 4 Months % Diagnosed Colon Cancer Patients 100% 95% 90% 85%
0% Cone Health Cancer Center
Similar Programs
All Commission on Cancer Approved Programs
5
2012 Cone Health Analytic Cases This table shows the occurrence of cancer in Guilford and the surrounding counties for 2012 by gender and stage of disease. It includes all new patients seen in 2012 within the Cone Health network. Primary Site
Total Stage Stage Stage Stage Stage UnAnalytic Male Female 0 I II III IV N/A known
Breast 589 Lung 440 Prostate 257 Colon/Rectum 245 Urinary Bladder 132 Brain/Spinal Cord/ Nervous System 106 Hodgkin/Non-Hodgkin Lymphoma 99 Corpus Uteri 88 Kidney 83 Thyroid 80 Pancreas 58 Lip/Oral Cavity/Pharynx 56 Leukemia 49 Multiple Myeloma 45 Melanoma Skin 35 Other Blood/Bone Marrow 35 Stomach 26 Liver 24 Ovary 24 Esophagus 22 Small Intestine 17 Larynx 15 Anus 15 Penis/Testis/Other Male 15 Endometrium/Vulva/ Other Female 14 Cervix 14 Renal Pelvis/Ureter/Urethra 13 Soft Tissue 7 Unknown Primary Site 35 All Others 53 Totals
6
2,691
5 584 118 236 167 47 17 1 3 240 200 2 131 34 80 186 1 6 257 0 0 47 168 19 22 0 1 132 113 29 38 52 64 52 0 10 104 28 83 29 10 3 5 0 2 42
64
0
0
0
0
0
106
0
58 41 0 88 46 37 15 65 34 24 44 12 28 21 20 25 19 16 21 14 17 9 14 10 0 24 18 4 7 10 12 3 8 7 15 0
0 25 24 19 28 0 3 0 60 4 14 6 0 4 0 52 7 7 16 1 0 0 54 6 10 4 0 6 0 5 9 10 28 0 6 2 12 7 10 24 0 1 0 0 0 0 0 49 0 0 0 0 0 0 45 0 4 13 7 5 4 0 2 0 0 0 0 0 35 0 0 4 5 6 8 1 2 0 8 3 3 7 1 2 0 7 1 11 3 0 2 1 4 2 8 7 0 0 0 3 5 6 2 1 0 1 4 6 1 3 0 0 0 4 5 4 0 0 2 2 9 2 0 0 1 1
0 14 0 14 6 7 4 3 15 20 23 30
1 4 1 3 2 3 0 1 8 2 1 2 0 0 6 4 0 2 1 0 0 0 4 0 2 1 0 0 0 1 0 0 0 34 0 0 4 2 9 11 24 3
1,204 1,487
250 770 529 344 439 303 56
Top Four Sites at Cone Health, 2008-2012 Our top four sites during the time period 2008-2012 have been consistently breast, lung, prostate and colorectal.
Number of Cases
700
Breast Lung Prostate Colon/Rectum
600 500 400 300 200 100 0 2009
2008
2010
2012
2011
Year of Diagnosis
Age at Diagnosis by Gender, 2012 Analytic Cases The prevalence of cancer increases sharply at age 40 for women and age 50 for men.
Number of Patients
450
Male Female
400 350 300 250 200 150 100 50 0
18-29
30-39
40-49
50-59
60-69
70-79
80-89
90+
Age at Diagnosis
85% Diagnosed and Treated at Cone Health
Class of Case, 2012 Analytic Cases A total of 2,691 analytic cases were diagnosed at Cone Health in 2012. Of those, 2274 (85 percent) were patients initially diagnosed and received all or part of their first course of treatment at Cone Health. Eleven percent or 296 patients were diagnosed elsewhere but came to Cone Health for part or all of their first course of treatment. Only 121 patients (4 percent) were diagnosed at Cone Health and went elsewhere for their first course of treatment.
4% 11% Diagnosed at Diagnosed Cone Health, Elsewhere, Treated Treated Elsewhere at Cone Health 7
Caring for You: From Research to Treatment to Community Outreach
Cancer Center Has First Patient in New Worldwide Clinical Trial When patients are offered the option to join a clinical trial, they take into account many factors to arrive at a decision. Linda Helsel was one of those patients offered a trial. She weighed the pros and cons of taking part in the trial. The most important factor that contributed to her decision is that she had received prior chemotherapy in 2005. She knew what that was like. She wanted to have the best possible quality of life. When she heard that the treatment in the clinical trial was not chemotherapy and the medicines were pills, she felt she had nothing to lose. Helsel was the first patient to enroll in an international study to treat first line metastatic breast cancer. Dr. Peter Rubin is the principal investigator of the study, entitled “An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive metastatic breast cancer.” At the time Helsel enrolled in the trial in February, she had symptoms that prevented her from sleeping, eating and enjoying life. She noticed improvement in her symptoms within 10 days. Within five months, she describes her quality of life as 100 percent better than a year ago. She has a few intermittent side effects from the study medications, and she knows how to take care of them. Gem mining, bass fishing, sight-seeing and even mowing the yard – Helsel is now able to enjoy these activities. The primary objective of this study is to determine if two drugs – everolimus combined with letrozole – are effective in stopping the progression of metastatic breast cancer. Everolimus is designed to work by stopping the growth and proliferation of the cancer cells along a specific pathway. According to Rubin, “This is an exciting study to test a new oral medication that selectively inhibits a pathway critical for cancer cell survival. We are hoping that this 8
Dr. Peter Rubin provides Linda Helsel with medications that are under study in a new worldwide clinical trial to test the efficacy of two drugs in stopping the progression of metastatic breast cancer. She is the first patient in the study.
combination of drugs will be even more effective when used earlier in the course of treatment. We are proud to be the first cancer center in the world to become a part of this trial. The fact that the Cone Health Cancer Center was selected says a lot about the caliber of our incredible research team.” The Food and Drug Administration approved everolimus (Afinitor, Novartis Pharmaceuticals Corporation) in July 2012 for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. In the current study, nicknamed BOLERO-4 (Breast cancer trials of OraL EveROlimus-4), everolimus and letrozole are given in combination as the first treatment for metastatic disease. Approximately 200 patients will be enrolled into the trial. The plan is to have a total of 70 sites taking part in this study, with 18 in the United States and 52 in the rest of the world. Advances in cancer treatment can only happen when patients like Helsel take part in clinical trials. Cone Health is grateful for the willingness of our patients to help us find better treatments to improve survival and quality of life for those in our communities.
Multidisciplinary Approach Improves Care Cone Health takes a multidisciplinary approach to cancer care in several ways – from tumor conferences and research to clinics and navigators. For example, in our tumor conferences, our caregivers discuss individual patients, their diagnoses and their care. All reasonable treatment options, including state-ofthe-art protocols, are considered in an open, roundtable discussion. Sixteen such tumor conferences are held each month and include pathologists, medical oncologists, surgeons and radiation oncologists who collaborate on plans for care for our patients. Another example is how pharmacy residents collaborated with oncologists to conduct a study to determine if chemotherapy patients stayed on their medicines as a result of repeated contact with and information from pharmacists. Results were compared to those of patients who were not periodically contacted. Study results are pending, but look promising.
Jill Berry (center) has questions about her cancer journey and seeks answers from patient navigators (from left) Tami Knutson, RN, Breast Cancer Center manager, and Dawn Stuart, RN.
Multidisciplinary clinics are another example of how we provide coordinated care. In our multidisciplinary clinics, we provide patients with access to multiple specialists in a single setting. Our multidisciplinary patient navigators serve as an excellent source for patients and families to help them lay the course for and maneuver through their cancer journey. Our emphasis on multidisciplinary care ensures that the care we provide is comprehensive, harmonic and coordinated.
Serving the Underserved We provide free or low-cost breast and cervical cancer screenings and follow-up care to underserved women as part of the stateadministered Breast and Cervical Cancer Control Program. Since the inception of BCCCP, we have seen 349 patients, 16 of whom were diagnosed with breast cancer and seven of whom were treated for cervical cancer. BCCCP is funded in part by a $50,000 grant from the NC Triad Affiliate for Susan G. Komen for the Cure and a major gift to Cone Health from David and Dr. Jo Ann Shaw.
9
Second Symposium Covers the Latest Cancer Trends The Cone Health Cancer Center jointly sponsored the Second Annual Dr. John Lusk Cone Health Oncology Symposium with the Greensboro Area Health Education Center and the University of North Carolina Eshelman School of Pharmacy. More than 70 physicians, physician assistants, nurses, nurse practitioners, pharmacists and other healthcare professionals attended the April 26, 2013, event to gain knowledge about current trends and treatment strategies. Faculty included Faera Byerly, MD, Central Carolina Surgery, PA; Lew Iacovelli, PharmD, Oncology Pharmacy Services, Cone Health Cancer Center; Kalsoom Khan, MD, Cone Health Cancer Center; Gabriel Lopez, MD, MD Anderson Cancer Center; Matthew Manning, MD, Piedmont Radiation Oncology; and Mohamed Mohamed, MD, Cone Health Cancer Center. This distinguished group of experts covered important topics such as: • Treatment options in radiation oncology for brain tumors. • New pharmaceutical agents utilized in oncology. • The diagnosis and treatment options for patients with lung cancer. • Beneficial treatments than can be safely integrated with conventional oncology treatments. • The latest treatment strategies in surgical oncology. • The rapidly progressing area of cancer genetics.
Study Addresses Health Disparities Cone Health continues to be an integral part of a fiveyear national study now underway in Greensboro and Pittsburgh. The Accountability for Cancer Care through Undoing Racism and Equity (ACCURE) study is an innovative attempt through the use of technology and other tools to equalize the care that African American and Caucasian breast and lung cancer patients receive. To date, the study has reached 67 patients served through Cone Health Cancer Center (19 former patients who have completed their cancer care and 48 patients in active treatment) with activities that include: interviews and focus groups to discover ways to enhance pathways of quality healthcare; the utilization of innovative nurse navigation protocols; and the development and use of an electronic medical record reporting system that creates alerts to staff when enrolled patients’ treatment has deviated from the recommended treatment plan. In the upcoming years, the study will evaluate a series of Healthcare Equity Trainings for staff, being developed in collaboration with physician champions and members from the academic-community partnership. The ACCURE study is funded by the National Cancer Institute and is being led as a collaborative effort between the University of North Carolina at Chapel Hill, The Partnership Project, Inc., Cone Health and the University of Pittsburgh Cancer Center. This study is a Community Based Participatory Research Project and is a continuation of the exploratory research managed by the Greensboro Health Disparities Collaborative and conducted from 2006 to 2009. The earlier project sought to understand more about the reasons for disparities between African American and white breast cancer patients.
“At every given moment we are absolutely perfect for what is required for our journey.” - Steve Maraboli 10
Multidisciplinary Thoracic Oncology Clinic
“No man ever steps in the same river twice, for it’s not the same river and he’s not the same man.” - Heraclitus
Teaming Up Against Lung Cancer: Evaluating non-small cell lung cancer and small cell lung cancer patient outcomes after treatment at the Multidisciplinary Thoracic Oncology Clinic
Fredrick Gainey, Quality/Process Improvement; Mohamed Mohamed, MD, PhD, Oncology; Dana Herndon, RN, Thoracic Oncology Nurse Navigator
Lung cancer is the leading cause of cancer mortality in the United States and the world. In 2013, it is estimated that more than 160,000 will die with lung cancer in the United States. Lung cancer kills twice the number of women than breast cancer and three times the number of men than prostate cancer. The average five-year survival for lung cancer is about 80 percent for Stage I but less than 5 percent for Stage IV. Early diagnosis and treatment is very important in improving survival. The quality of cancer care is complex and depends on careful coordination between multiple treatments and providers, and technical information exchange and regular communication flow between all those involved in treatment. Advances in surgical procedures, chemotherapy, computer technology, targeted molecular and radiation therapies have all led to an increase in multimodality therapy, which increases the number of interfaces among cancer specialist and other clinicians in the treatment of any single patient. Each failure in communication between various physicians and care providers, and every transition and interface miscue can result in delayed treatment planning and implementation, unnecessary duplication of tests, incomplete follow-up, increased patient anxiety, decreased patient satisfaction and declines in quality of life. The care for lung cancer patients is widely spread among different medical subspecialties, including primary care physicians, pulmonologists, radiologists, pathologists, thoracic surgeons, medical oncologists and radiation oncologists. The majority of these patients also require assistance from social workers, dietitians, psychologists, pharmacists and financial counselors. Even with the help of their families, it is extremely difficult for patients with lung cancer to go to all these appointments, which are usually in different locations. This also leads to significant delay in diagnosis and initiation of treatment for these patients. 11
Cone Health understood the challenges facing these patients in our community. Our multidisciplinary approach provides the most comprehensive care for each person diagnosed with cancer. This approach allows us to utilize the skills of specialists in every discipline to determine the most effective and complete treatments for all types of cancer. It was developed to facilitate early diagnosis and treatment of lung tumors using a team approach. Our program provides personalized care for each patient by a team of dedicated professionals who represent specific specialties. This multidisciplinary approach allows our physicians to provide patients with an optimal treatment plan. This approach results in earlier treatment, enhanced coordination of care, and increased patient and physician satisfaction. A group of well-trained physicians in the field of lung cancer who are very compassionate about the care of their patients decided to take a different approach to provide better, efficient and prompt care for lung cancer patients in our community. We developed a weekly thoracic conference where all the above physicians meet, discuss new and recurrent lung cancer cases, and create the most appropriate diagnostic or treatment plan for these patients. We also developed a Multidisciplinary Thoracic Oncology Clinic on a weekly basis. In this clinic, the patient will be seen by the team of treating physicians, lung navigator, social worker and pharmacist in the same room, avoiding multiple office visits. A treatment plan is usually discussed between the team of treating physicians as well as the patient and his/her family. Treatment would normally start within days of that visit. A lung cancer navigator position was created to help eliminate barriers to healthcare. The navigator plays a very important role in coordinating the care of lung cancer patients among the different physicians, provide resources and help the patients through their journey from the time they are found to have an abnormal imaging study until completion of the therapy. The goal for the patient navigator is to eliminate barriers to care and ensure timely delivery of services. This is done through one-on-one contact between the navigator and patients to assess his or her needs. The navigator’s phone number and email are very valuable points of contact for the referring physicians, care team, and the patients and their families. 12
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Age Distribution of Patient Population
Age Distribution of Patient Population
66% 65 Years of Age and Older
72% 65 Years of Age and Older 28% Less than 65 Years of Age
34% Less than 65 Years of Age
Race Distribution of Patient Population
Race Distribution of Patient Population
78% White
77% White
20% Black
21% Black
3% Other
1% Other
Tobacco Status of Patient Population
51% Previous Tobacco User
38% Current Tobacco User
2% Unknown
9% Never Used Tobacco
Tobacco Status of Patient Population
48% Previous Tobacco User
43% Current Tobacco User
5% 4% Unknown Never Used Tobacco
Two interesting outcome were seen in this study. The first showed a significant statistical difference in survival in patients with Non-Small Cell Lung Cancer who receive initial cancer treatment within two weeks after diagnoses compared to those who received it after two weeks of diagnosis, no matter where the treatment was given. This strongly supports our multidisciplinary approach by starting treatment within days after diagnosis. Lung cancer is a very complicated disease, and no one single specialty can treat it alone. Every day brings more hope and more options for our patients. Our diagnostic team utilizes the most advanced approach such as electromagnetic navigational bronchoscopy to diagnose lung cancer in areas that were difficult to reach in the past. Thoracic surgery uses the least invasive approach for resection of early stage lung cancer. Radiation Oncology has the most advanced stereotactic body and brain radiotherapy. Our Medical Oncology team tailors the treatment on an individual basis in this era of personalized medicine. Patients receive chemotherapy or targeted oral biologics based on their cancer histology, molecular studies and gene mutations, among other factors. We conclude from this small study that taking a multidisciplinary approach to the care of lung cancer patients is essential for their survival and well-being. Coordination and a team approach should be the standard of care for this disease. At Cone Health, we put our patients first and will do whatever it takes to improve the care for patients in our community.
Survivorship of Non-Small Cell Lung Cancer Patients Treated at Cone Cancer Center Multidisciplinary Thoracic Oncology Clinic vs. No Multidisciplinary Thoracic Oncology Clinic 100
100
90 80 70 Number of Patients
The Multidisciplinary Thoracic Oncology Clinic was developed five years ago. We decided to run a small study on a sample of lung cancer patients treated in 2011 and 2012 at the clinic versus patients treated outside the clinic to see if the multidisciplinary approach had any significant impact on the survival of lung cancer patients. The sample size was 299 patients. The percentage of non-small cell lung cancer patients versus small cell lung cancer patients was as expected – 75 to 25 percent. The majority of patients with non-small cell lung cancer were older than 65 (66 percent), with males representing 57 percent. Current smokers were only 35 percent, and the majority of the patients were former or never smokers.
60 49
50
44
40 29
30 20 10 0
Alive
Deceased
Multidisciplinary Thoracic Oncology Clinic
(Non-small cell lung carcinoma)
67% Alive
33% Deceased
40% Alive 60% Deceased
Alive
Deceased
No Multidisciplinary Thoracic Oncology Clinic
(Non-small cell lung carcinoma)
Survivorship Percentage for Non-Small Cell Lung Cancer Patients Treated by Multidisciplinary Thoracic Oncology Clinic
Survivorship Percentage for Non-Small Cell Lung Cancer Patients Not Treated by Multidisciplinary Thoracic Oncology Clinic 13
About Us The Moses H. Cone Memorial Hospital
Alamance Regional Medical Center
Wesley Long Hospital
Cone Health is a not-for-profit network of healthcare providers serving people in Guilford, Forsyth, Rockingham, Alamance, Randolph Caswell and surrounding counties. Our tagline – “The Network for Exceptional Care” – highlights our commitment to excellence, which is shared by our more than 10,000 professionals, 1,300 physicians and 1,200 volunteers. As one of the region’s largest and most comprehensive health networks, Cone Health has more than 100 locations, including six hospitals, two medical centers, four urgent care centers, 95 physician practice sites and multiple centers of excellence. The Moses H. Cone Memorial Hospital is our flagship. Moses Cone Hospital is a 536-bed teaching hospital and referral center. It includes a Pediatric Emergency Department, Level II Trauma Center and centers of excellence such as the Orthopedics Center, Neurosciences Center, Stroke Center and Heart and Vascular Center. North Tower opened in 2013 with 16 new operating rooms and all private patient rooms. Alamance Regional Medical Center, a 238-bed medical and surgical hospital in Alamance County, joined Cone Health in May 2013. Specialized services include a Heart & Vascular Center, Alamance Regional Cancer Center, Women’s Care Center, advanced imaging services and surgical services among others.
Women’s Hospital
Annie Penn Hospital
Wesley Long Hospital offers 175 private beds for medical and surgical patients with service areas focused on oncology, bariatric surgery, urology and orthopedics. Our modern facility utilizes state-of-the-art equipment such as the da Vinci® surgical robot system and the SpyGlass® visualization system in the Endoscopy Center. The campus also houses the Cancer Center, Sleep Disorders Center, Wound Care, Sickle Cell Medical Center and Hyperbaric Center and Surgery Center. Women’s Hospital, a 134-bed facility, is home to one of the area’s most experienced neonatal intensive care teams. The hospital’s Level II and Level III unit has been providing care to critically ill newborns since 1990. The hospital also houses the nationally accredited Breast and Ultrasound Imaging Center. The hospital’s da Vinci robot provides minimally invasive surgical care for gynecology patients. Annie Penn Hospital has 110 acute care beds. This facility includes inpatient and short stay surgery centers, Cone Health Cancer Center at Annie Penn, LeBauer HeartCare at Annie Penn and specialty clinics such as a Sleep Disorders Center and an Endoscopy Center of Excellence.
Behavioral Health Hospital
14
The Behavioral Health Hospital offers pediatric and adult inpatient crisis stabilization. The 80-bed facility accommodates 50 adults and 30 adolescents. Outpatient care includes numerous group therapy programs as well as individual counseling and day programs. The hospital also offers the community a 24-hour Helpline that provides access to a trained professional. Three additional outpatient Behavioral Health Centers also are located in Greensboro, Kernersville and Reidsville.
Our Locations Oncology Headquarters & Research Center A
Cone Health Cancer Center at Wesley Long Hospital
Oncology Treatment & Research Centers B
Randolph Cancer Center at Randolph Hospital
Additional Oncology Centers & Support C
Cone Health Cancer Center at Annie Penn Hospital
D
Cone Health Cancer Center at MedCenter of High Point
E
Cone Health Cancer Center at Caswell Family Medical Center
F
Cone Health Cancer Center at Alamance Regional Medical Center
ROCKINGHAM
CASWELL 158
REIDSVILLE
E
C
159
29
ALAMANCE
BUS
40
HIGH POINT
GREENSBORO
A
D
40
F
85
GUILFORD
BUS
85
ASHEBORO
B
64
RANDOLPH
15
The only journey is the one within. - Rainer Maria Rilke
Cone Health 1200 N. Elm St. Greensboro, NC 27401 conehealth.com